Lunaphore Technologies, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, has appointed Matthias Weber, former President of Leica Biosystems, to its Board of Directors. Weber has been appointed to represent the interests of strategic investor PHC Holdings Corporation (PHCHD), who previously invested in Lunaphore through a Series C financing round in 2020.
Weber brings extensive experience in the cancer diagnostics and immunohistochemistry fields, marked by excellence in a range of diverse strategic roles including Product Management, R&D, Operations, Sales & Marketing, and most notably as President at Leica Biosystems, a position which he held between 2012 and 2019. Weber commented: “I am delighted to join Lunaphore’s Board and to be part of a great team of innovators that will change the future of immunohistochemistry and cancer diagnostics.”
“Especially in the field of immuno-oncology, the Lunaphore high-plex staining technology offers researchers unique opportunities to simultaneously identify multiple markers while preserving the morphology of the tissue and cells,” he added.
PHCHD, a global healthcare company, led Lunaphore’s CHF25 million Series C financing round as announced in early 2020. Following the investment, PHCHD’s subsidiary Epredia, a global leader in precision cancer diagnostics, secured a comprehensive exclusive distribution agreement for Lunaphore’s flagship LabSat Research platform. With the appointment of Weber as part of the PHCHD investment, the company aims to strengthen its position in the field of spatial biology. Weber’s expert engagement will be instrumental in assisting the efforts to consolidate the company as a leading provider of innovative solutions for immuno-oncology research and tissue analysis.
Lunaphore’s Chairman of the Board, Joe Bernardo, commented: “I am excited to have Matthias Weber, MD join our Board. Matthias is a great business leader with global experience at GE Healthcare and Danaher. The industry knowledge acquired during his seven years at the helm of Leica Biosystems, especially in the area of immunohistochemistry, will help us to fully exploit the company’s potential by supporting Lunaphore with the creation of a world class network of KOLs, providing guidance to achieve successful instrument launches into global markets and building strategic partnerships.”